Improvement of insulin sensitivity in obese Zucker rats by myricetin extracted from Abelmoschus moschatus

Planta Medica

Volumn 73, Issue 10, 2007, Pages 1054-1060

  Liu, I Min ^a   Tzeng, Thing Fong ^b   Liou, Shorong Shii ^a   Lan, Ting Wei ^a  

^a TAJEN UNIVERSITY   (Taiwan)

^b Pao Chien Hospital   (Taiwan)

Author keywords

Abelmoschus moschatus; Akt; Glucose transporter subtype 4; Insulin receptor; Insulin receptor substrate 1; Malvaceae; Myricetin; Obese Zucker rat; Phosphatidylinositol 3 kinase

Indexed keywords

ABELMOSCHUS MOSCHATUS EXTRACT; GLUCOSE TRANSPORTER 4; INSULIN RECEPTOR SUBSTRATE 1; MYRICETIN; PLANT EXTRACT; UNCLASSIFIED DRUG;

ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; INSULIN SENSITIVITY; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SOLEUS MUSCLE; ZUCKER DIABETIC FATTY RAT;

ABELMOSCHUS; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS; FLAVONOIDS; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; INSULIN RESISTANCE; OBESITY; PHYTOTHERAPY; RATS; RATS, ZUCKER;

ABELMOSCHUS MOSCHATUS; ANIMALIA; MALVACEAE; RATTUS;

EID: 34548614885     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-981577     Document Type: Article

References (23)

1. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106: 171-6.
2. Younis N, Soran H, Farook S. The prevention of type 2 diabetes mellitus: recent advances. QJM 2004; 97: 451-5.
3. Bown D. Encyclopaedia of Herbs and their Uses. London: Dorling Kindersley; 1995.
4. Ong KC, Khoo HE. Biological effects of myricetin. Gen Pharmacol 1997; 29: 121-6.
5. Ong KC, Khoo HE. Insulinomimetic effects of myricetin on lipogenesis and glucose transport in rat adipocytes but not glucose transport translocation. Biochem Pharmacol 1996; 51: 423-9.
6. Ong KC, Khoo HE. Effects of myricetin on glycemia and glycogen metabolism in diabetic rats. Life Sci 2000; 67: 1695-705.
7. Liu IM, Liou SS, Lan TW, Hsu FL, Cheng JT. Myricetin as the active principle of Abelmoschus moschatus to lower plasma glucose in streptozotocin-induced diabetic rats. Planta Med 2005; 71: 617-21.
8. Liu IM, Liou SS, Lan TW, Hsu FL, Cheng JT. Mediation of β-endorphin by myricetin to lower plasma glucose in streptozotocin-induced diabetic rats. J Ethnopharmacol 2006; 104: 199-206.
9. Bray GA. The Zucker-fatty rat: a review. Fed Proc 1977; 36: 148-53.
10. Griffiths LA, Smith GE. Metabolism of myricetin and related compounds in the rat. Metabolite formation in vivo and by the intestinal microflora in vitro. Biochem J 1972; 130: 141-51.
11. Rouru J, Huupponen R, Pesonen U, Koulu M. Subchronic treatment with metformin produces anorectic effect and reduces hyperinsulinemia in genetically obese Zucker rats. Life Sci 1992; 50: 1813-20.
12. Cefalu WT, Wang ZQ, Zhang XH, Baldor LC, Russell JC. Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats. J Nutr 2002; 132: 1107-11.
13. Ahren B, Pacini G. Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. Eur J Endocrinol 2004; 150: 97-104.
14. Christ CY, Hunt D, Hancock J, Garcia-Macedo R, Mandarino LJ, Ivy JL. Exercise training improves muscle insulin resistance but not insulin receptor signaling in obese Zucker rats. J Appl Physiol 2002; 92: 736-44.
15. Giorgino F, Laviola L, Leonardini A. Pathophysiology of type 2 diabetes: rationale for different oral antidiabetic treatment strategies. Diabetes Res Clin Pract 2005; 68: S22-9.
16. Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs 2003; 63: 1879-94.
17. Petersen KF, Shulman GI. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am J Cardiol 2002; 90: G11-8.
18. Song XM, Ryder JW, Kawano Y, Chibalin AV, Krook A, Zierath JR. Muscle fiber type specificity in insulin signal transduction. Am J Physiol 1999; 277: R1690-6.
19. Sesti G, Federici M, Hribal ML, Lauro D, Sbraccia P, Lauro R. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J 2001; 15: 2099-111.
20. Anai M, Funaki M, Ogihara T, Terasaki J, Inukai K, Katagiri H et al. Altered expression levels and impaired steps in the pathway to phosphatidylinositol 3-kinase activation via insulin receptor substrates 1 and 2 in Zucker fatty rats. Diabetes 1998; 47: 13-23.
21. Carvalho E, Rondinone C, Smith U. Insulin resistance in fat cells from obese Zucker rats-evidence for an impaired activation and translocation of protein kinase B and glucose transporter 4. Mol Cell Biol 2000; 206: 7-16.
22. Kern M, Wells JA, Stephens JM, Elton CW, Friedman JE, Tapscott EB et al. Insulin responsiveness in skeletal muscle is determined by glucose transporter (Glut4) protein level. Biochem J 1999; 270: 397-400.
23. Ivy JL. Muscle insulin resistance amended with exercise training: role of GLUT4 expression. Med Sci Sports Exerc 2004; 36: 1207-11.